ReviewTexas Heart Institute journal2011
CD34-positive stem cells: in the treatment of heart and vascular disease in human beings.
Review in Texas Heart Institute journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 1 synthesis or guideline pooled it, 138 citations in OpenAlex.
- Pooled it
- Autologous CD34+ Stem Cell Therapy Increases Coronary Flow Reserve and Reduces Angina in Patients With Coronary Microvascular Dysfunction.Circulation. Cardiovascular interventions · 2022Trial
- The effect of polyphenol-rich chardonnay seed supplements on peripheral endothelial function.European journal of nutrition · 2020Trial
- PreSERVE-AMI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intracoronary Administration of Autologous CD34+ Cells in Patients With Left Ventricular Dysfunction Post STEMI.Circulation research · 2017Trial
- Heat therapy promotes the expression of angiogenic regulators in human skeletal muscle.American journal of physiology. Regulatory, integrative and comparative physiology · 2016Trial
- DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.Cardiovascular diabetology · 2014Trial
- Preclinical and clinical phase I studies of a new recombinant Filgrastim (BK0023) in comparison with Neupogen®.BMC pharmacology & toxicology · 2014Trial
- Trial
- Autologous Cell Therapy for Chronic Limb Threatening Ischemia: Towards Personalized Medicine.Angiology · 2026Review
- The Broken Cradle: Bone Marrow Stem Cell Niche Remodelling in Diabetes.Stem cell reviews and reports · 2026Review
- Randomized Study of Intravitreal Autologous CD34+ Stem Cells in Central Retinal Vein Occlusion (Treatment of Retinal vein occlusion Using STem cells [TRUST] Report 1): Safety and Feasibility.Ophthalmology science · 2026Article
- The mechanism of promoting angiogenesis after cerebral infarction by scalp acupuncture based on MATN2/WNT3a/β-catenin.Journal of molecular histology · 2025Article
- Therapeutic Potential and Mechanisms of Mesenchymal Stem Cells in Coronary Artery Disease: Narrative Review.International journal of molecular sciences · 2025Review
- CD34Theranostics · 2025Article
- Black Chokeberry (Life (Basel, Switzerland) · 2024Article
- Smoking and Diabetes Attenuate Number of CD34International journal of molecular sciences · 2023Article
- Association between serum albumin levels and height loss in Japanese workers: a retrospective study.Journal of physiological anthropology · 2023Article
- Article
- CD34-Structure, Functions and Relationship with Cancer Stem Cells.Medicina (Kaunas, Lithuania) · 2023Review
- CD34 positive cells as endothelial progenitor cells in biology and medicine.Frontiers in cell and developmental biology · 2023Review
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Bone marrow-derived CD34(+) cells are a well-characterized population of stem cells that have traditionally been used clinically to reconstitute the hematopoietic system after radiation or chemotherapy. More recently, CD34(+) cells have also been shown to induce therapeutic angiogenesis in animal models of myocardial, peripheral, and cerebral ischemia. The mechanism by which CD34(+) cells promote therapeutic angiogenesis is not completely understood, although evidence supports both direct incorporation of the cells into the expanding vasculature and paracrine secretion of angiogenic growth factors that support the developing microvasculature. Phase I and phase II clinical trials have explored the usefulness of CD34(+) cells in the treatment of ischemic conditions in human patients. As the population of patients diagnosed with some form of ischemic cardiovascular disease expands, the need for more effective treatments also grows, especially in patients who are refractory to standard pharmacologic or revascularization treatment. As phase III trials begin, CD34(+) cells will be definitively tested as a novel treatment for myocardial and peripheral ischemia. This review will discuss what is known about the CD34 antigen and the cells that harbor it, the preclinical evidence supporting the therapeutic potential of CD34(+) cells in ischemic models, and, last, the current evidence for the clinical usefulness of CD34(+) cells in the treatment of human ischemic disease.
Indexed as
Identifiers
22163120PMC3231531W147224080What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.